{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:39:48Z","timestamp":1790361588445,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75990-1","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T02:04:40Z","timestamp":1730253880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling"],"prefix":"10.1038","volume":"14","author":[{"given":"Ying","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania M.","family":"V\u00e1zquez-Blomquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guirong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Perea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"75990_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang, M., Herbst, R. S. & Boshoff, C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat. Med. 27, 1345\u20131356 (2021).","journal-title":"Nat. Med."},{"key":"75990_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the \u2018undruggable\u2019 cancer targets. Nat. Rev. Cancer 17, 502\u2013508 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"75990_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trecan.2015.11.003","volume":"2","author":"KA Lipinski","year":"2016","unstructured":"Lipinski, K. A. et al. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2, 49\u201363 (2016).","journal-title":"Trends Cancer"},{"key":"75990_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4143\/crt.2022.078","volume":"54","author":"J Rivera-Concepcion","year":"2022","unstructured":"Rivera-Concepcion, J., Uprety, D. & Adjei, A. A. Challenges in the use of targeted therapies in non-small cell lung cancer. Cancer Res. Treat. 54, 315\u2013329 (2022).","journal-title":"Cancer Res. Treat."},{"key":"75990_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/CCO.0000000000000592","volume":"32","author":"R Pirker","year":"2020","unstructured":"Pirker, R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr. Opin. Oncol. 32, 63\u201367 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"75990_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115609","volume":"9","author":"CE Ortega","year":"2014","unstructured":"Ortega, C. E., Seidner, Y. & Dominguez, I. Mining CK2 in cancer. PLoS One 9, e115609 (2014).","journal-title":"PLoS One"},{"key":"75990_CR7","doi-asserted-by":"crossref","unstructured":"Chua, M. M. J. et al. CK2 in cancer: Cellular and biochemical mechanisms and potential therapeutic target. Pharmaceuticals (Basel). 10 (2017).","DOI":"10.3390\/ph10010018"},{"key":"75990_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20021469","volume":"369","author":"DW Litchfield","year":"2003","unstructured":"Litchfield, D. W. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1\u201315 (2003).","journal-title":"Biochem. J."},{"key":"75990_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.18632\/oncotarget.948","volume":"4","author":"JP Turowec","year":"2013","unstructured":"Turowec, J. P., Vilk, G., Gabriel, M. & Litchfield, D. W. Characterizing the convergence of protein kinase CK2 and caspase-3 reveals isoform-specific phosphorylation of caspase-3 by CK2\u03b1\u2019: Implications for pathological roles of CK2 in promoting cancer cell survival. Oncotarget 4, 560\u2013571 (2013).","journal-title":"Oncotarget"},{"key":"75990_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/onc.2012.165","volume":"32","author":"A Deshiere","year":"2013","unstructured":"Deshiere, A. et al. Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction. Oncogene 32, 1373\u20131383 (2013).","journal-title":"Oncogene"},{"key":"75990_CR11","first-page":"215","volume":"22","author":"I Yaylim","year":"2002","unstructured":"Yaylim, I. & Isbir, T. Enhanced casein kinase II (CK II) activity in human lung tumours. Anticancer Res. 22, 215\u2013218 (2002).","journal-title":"Anticancer Res."},{"key":"75990_CR12","doi-asserted-by":"publisher","first-page":"16134","DOI":"10.1038\/s41598-017-16012-1","volume":"7","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. Association of protein kinase CK2 inhibition with cellular radiosensitivity of non-small cell lung cancer. Sci. Rep. 7, 16134 (2017).","journal-title":"Sci. Rep."},{"key":"75990_CR13","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-15-2888","volume":"76","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. CK2\u03b1\u2019 drives lung cancer metastasis by targeting BRMS1 nuclear export and degradation. Cancer Res. 76, 2675\u20132686 (2016).","journal-title":"Cancer Res."},{"key":"75990_CR14","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1039\/D1OB00257K","volume":"19","author":"J Iegre","year":"2021","unstructured":"Iegre, J. et al. Chemical probes targeting the kinase CK2: A journey outside the catalytic box. Org. Biomol. Chem. 19, 4380\u20134396 (2021).","journal-title":"Org. Biomol. Chem."},{"key":"75990_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1471-2407-9-146","volume":"9","author":"AM Solares","year":"2009","unstructured":"Solares, A. M. et al. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 9, 146 (2009).","journal-title":"BMC Cancer"},{"key":"75990_CR16","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1158\/0008-5472.CAN-10-1893","volume":"70","author":"A Siddiqui-Jain","year":"2010","unstructured":"Siddiqui-Jain, A. et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288\u201310298 (2010).","journal-title":"Cancer Res."},{"key":"75990_CR17","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/0008-5472.CAN-04-2086","volume":"64","author":"SE Perea","year":"2004","unstructured":"Perea, S. E. et al. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64, 7127\u20137129 (2004).","journal-title":"Cancer Res."},{"key":"75990_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ijc.23013","volume":"122","author":"Y Perera","year":"2008","unstructured":"Perera, Y. et al. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int. J. cancer 122, 57\u201362 (2008).","journal-title":"Int. J. cancer"},{"key":"75990_CR19","doi-asserted-by":"publisher","first-page":"14689","DOI":"10.1038\/s41598-020-71854-6","volume":"10","author":"MF Gottardo","year":"2020","unstructured":"Gottardo, M. F. et al. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization. Sci. Rep. 10, 14689 (2020).","journal-title":"Sci. Rep."},{"key":"75990_CR20","doi-asserted-by":"crossref","unstructured":"Perera, Y. et al. Clinical-grade peptide-based inhibition of CK2 blocks viability and proliferation of T-ALL cells and counteracts IL-7 stimulation and stromal support. Cancers (Basel). 12 (2020).","DOI":"10.3390\/cancers12061377"},{"key":"75990_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.18632\/oncotarget.1513","volume":"5","author":"LR Martins","year":"2014","unstructured":"Martins, L. R. et al. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor. Oncotarget 5, 258\u2013263 (2014).","journal-title":"Oncotarget"},{"key":"75990_CR22","doi-asserted-by":"crossref","unstructured":"Rosales, M. et al. Targeting of protein kinase CK2 in acute myeloid leukemia cells using the clinical-grade synthetic-peptide CIGB-300. Biomedicines. 9 (2021).","DOI":"10.1101\/2021.05.19.444866"},{"key":"75990_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-020-03747-1","volume":"470","author":"Y Perera","year":"2020","unstructured":"Perera, Y. et al. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome. Mol. Cell. Biochem. 470, 63\u201375 (2020).","journal-title":"Mol. Cell. Biochem."},{"key":"75990_CR24","doi-asserted-by":"crossref","unstructured":"P\u00e9rez, G. V et al. CIGB-300 anticancer peptide differentially interacts with CK2 subunits and regulates specific signaling mediators in a highly sensitive large cell lung carcinoma cell model. Biomedicines. 11 (2022).","DOI":"10.3390\/biomedicines11010043"},{"key":"75990_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.yexcr.2011.04.011","volume":"317","author":"HG Farina","year":"2011","unstructured":"Farina, H. G. et al. CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. Exp. Cell Res. 317, 1677\u20131688 (2011).","journal-title":"Exp. Cell Res."},{"key":"75990_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2016.05.026","volume":"107","author":"F Benavent Acero","year":"2017","unstructured":"Benavent Acero, F. et al. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung Cancer 107, 14\u201321 (2017).","journal-title":"Lung Cancer"},{"key":"75990_CR27","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1021\/mp4006062","volume":"11","author":"FR Benavent Acero","year":"2014","unstructured":"Benavent Acero, F. R. et al. Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines. Mol. Pharm. 11, 1798\u20131807 (2014).","journal-title":"Mol. Pharm."},{"key":"75990_CR28","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/djq279","volume":"102","author":"AF Gazdar","year":"2010","unstructured":"Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L. & Minna, J. D. Lung cancer cell lines as tools for biomedical discovery and research. J. Natl. Cancer Inst. 102, 1310\u20131321 (2010).","journal-title":"J. Natl. Cancer Inst."},{"key":"75990_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11010-015-2370-x","volume":"404","author":"Y Perera","year":"2015","unstructured":"Perera, Y. et al. Pharmacologic inhibition of the CK2-mediated phosphorylation of B23\/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis. Mol. Cell. Biochem. 404, 103\u2013112 (2015).","journal-title":"Mol. Cell. Biochem."},{"key":"75990_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12864-023-09472-5","volume":"24","author":"D V\u00e1zquez-Blomquist","year":"2023","unstructured":"V\u00e1zquez-Blomquist, D. et al. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines. BMC Genomics 24, 373 (2023).","journal-title":"BMC Genomics"},{"key":"75990_CR31","first-page":"215","volume":"18","author":"Y Perera","year":"2012","unstructured":"Perera, Y. et al. Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. J. Pept. Sci. Off Publ. Eur. Pept. Soc. 18, 215\u2013223 (2012).","journal-title":"J. Pept. Sci. Off Publ. Eur. Pept. Soc."},{"key":"75990_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834814","volume":"9","author":"M Rosales","year":"2022","unstructured":"Rosales, M. et al. CIGB-300-regulated proteome reveals common and tailored response patterns of AML cells to CK2 inhibition. Front. Mol. Biosci. 9, 834814 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"75990_CR33","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka, Z. et al. COSMIC: A curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 52, D1210\u2013D1217 (2024).","journal-title":"Nucleic Acids Res."},{"key":"75990_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"75990_CR35","first-page":"760","volume":"20","author":"S Reissmann","year":"2014","unstructured":"Reissmann, S. Cell penetration: Scope and limitations by the application of cell-penetrating peptides. J. Pept. Sci. Off Publ. Eur. Pept. Soc. 20, 760\u2013784 (2014).","journal-title":"J. Pept. Sci. Off Publ. Eur. Pept. Soc."},{"key":"75990_CR36","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/molecules200713313","volume":"20","author":"T Skotland","year":"2015","unstructured":"Skotland, T., Iversen, T. G., Torgersen, M. L. & Sandvig, K. Cell-penetrating peptides: Possibilities and challenges for drug delivery in vitro and in vivo. Molecules 20, 13313\u201313323 (2015).","journal-title":"Molecules"},{"key":"75990_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/viro.1998.9400","volume":"252","author":"RH Stauber","year":"1998","unstructured":"Stauber, R. H. & Pavlakis, G. N. Intracellular trafficking and interactions of the HIV-1 Tat protein. Virology 252, 126\u2013136 (1998).","journal-title":"Virology"},{"key":"75990_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3762\/bjnano.11.10","volume":"11","author":"I Ruseska","year":"2020","unstructured":"Ruseska, I. & Zimmer, A. Internalization mechanisms of cell-penetrating peptides. Beilstein J. Nanotechnol. 11, 101\u2013123 (2020).","journal-title":"Beilstein J. Nanotechnol."},{"key":"75990_CR39","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2007-12-130211","volume":"112","author":"Y Zhou","year":"2008","unstructured":"Zhou, Y., Du, W., Koretsky, T., Bagby, G. C. & Pang, Q. TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 112, 2474\u20132483 (2008).","journal-title":"Blood"},{"key":"75990_CR40","doi-asserted-by":"publisher","first-page":"42409","DOI":"10.1038\/srep42409","volume":"7","author":"C Borgo","year":"2017","unstructured":"Borgo, C. et al. Generation and quantitative proteomics analysis of CK2\u03b1\/\u03b1\u2019((-\/-)) cells. Sci. Rep. 7, 42409 (2017).","journal-title":"Sci. Rep."},{"key":"75990_CR41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/jcb.24887","volume":"115","author":"F Qaiser","year":"2014","unstructured":"Qaiser, F. et al. Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function. J. Cell. Biochem. 115, 2103\u20132115 (2014).","journal-title":"J. Cell. Biochem."},{"key":"75990_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11010-017-3081-2","volume":"436","author":"B Yang","year":"2017","unstructured":"Yang, B., Yao, J., Li, B., Shao, G. & Cui, Y. Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML. Mol. Cell. Biochem. 436, 87\u201397 (2017).","journal-title":"Mol. Cell. Biochem."},{"key":"75990_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2012.02.032","volume":"322","author":"J Bliesath","year":"2012","unstructured":"Bliesath, J. et al. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett. 322, 113\u2013118 (2012).","journal-title":"Cancer Lett."},{"key":"75990_CR44","first-page":"1537","volume":"35","author":"KS So","year":"2015","unstructured":"So, K. S. et al. AKT\/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. Anticancer Res. 35, 1537\u20131542 (2015).","journal-title":"Anticancer Res."},{"key":"75990_CR45","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1021\/pr100728v","volume":"9","author":"A Rodr\u00edguez-Ulloa","year":"2010","unstructured":"Rodr\u00edguez-Ulloa, A. et al. Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells. J. Proteome Res. 9, 5473\u20135483 (2010).","journal-title":"J. Proteome Res."},{"key":"75990_CR46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1158\/1535-7163.MCT-08-1056","volume":"8","author":"Y Perera","year":"2009","unstructured":"Perera, Y. et al. Anticancer peptide CIGB-300 binds to nucleophosmin\/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol. Cancer Ther. 8, 1189\u20131196 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"75990_CR47","doi-asserted-by":"crossref","unstructured":"Firnau, M.-B. & Brieger, A. CK2 and the hallmarks of cancer. Biomedicines. 10 (2022).","DOI":"10.3390\/biomedicines10081987"},{"key":"75990_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s13402-020-00566-w","volume":"43","author":"C D\u2019Amore","year":"2020","unstructured":"D\u2019Amore, C., Borgo, C., Sarno, S. & Salvi, M. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance. Cell. Oncol. (Dordr) 43, 1003\u20131016 (2020).","journal-title":"Cell. Oncol. (Dordr)"},{"key":"75990_CR49","doi-asserted-by":"crossref","unstructured":"Gou, Q. et al. Inhibition of CK2\/ING4 pathway facilitates non-small cell lung cancer immunotherapy. Adv. Sci. 10 e2304068 (Weinheim, Baden-Wurttemberg, Ger., 2023).","DOI":"10.1002\/advs.202304068"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75990-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75990-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:03:16Z","timestamp":1730487796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75990-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75990"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75990-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were operated according to the Guide for the Care and Use of Laboratory Animals (Eighth Edition) issued by The National Academics (Washington, DC), Animal Ethics Committee of Hunan Provincial Research Center for Safety Evaluation of Drugs and ARRIVE Guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"26038"}}